The ESMO Congress is Europe’s largest and most prestigious cancer meeting, bringing together more than 33,000 clinicians, scientists, and industry experts.
Michael’s research focuses on the use of supercomputing to design next-generation cancer vaccines. His study assessed neoantigen prediction in glioma, comparing the performance of leading computational tools across large-scale datasets to identify shared vaccine targets in brain tumours. The work was recognised for its methodological innovation and potential to inform new immunotherapy strategies in neuro-oncology.
The study forms part of the UK Cancer Vaccine AI & Supercomputer Project, which aims to accelerate the development of cancer vaccines through the use of sovereign AI infrastructure. The initiative, led by teams at the University of Oxford with infrastructure leadership from The University of Cambridge, represents one of the UK’s flagship efforts to combine computational and translational oncology.
Read the full story on the Oxford Cancer website.